HIM
RPTP

Hillsdale Investment Management’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Hillsdale Investment Management’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,900
Closed -$49K – 637
2014
Q1 		$49K Buy
+4,900
New +$70.8K 0.01% 443

Other funds holding RPTP

CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Hillsdale Investment Management's RPTP Position: Q2 2014 in Review

Hillsdale Investment Management sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q2 2014, closing a stake of 4,900 shares — an estimated $49K sold.

Hillsdale Investment Management first reported a position in RPTP in Q1 2014 and held it in 1 quarter. The position peaked at $49K in Q1 2014. 74 funds tracked by Wall St. Rank hold RPTP as of Q2 2014.

  • Hillsdale Investment Management reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q2 2014 after selling out during the quarter.
  • Hillsdale Investment Management sold 4,900 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q2 2014, an estimated $49K.
  • Hillsdale Investment Management first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q1 2014 and held it in 1 quarter.
  • Hillsdale Investment Management's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $49K in Q1 2014.
  • 74 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q2 2014.

Based on Hillsdale Investment Management's 13F filing for Q2 2014, filed 13 Aug 2014.